The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
Authors
Keywords
-
Journal
npj Vaccines
Volume 3, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-07-04
DOI
10.1038/s41541-018-0057-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial
- (2017) S.B. Sirima et al. VACCINE
- A Functional Role for Antibodies in Tuberculosis
- (2016) Lenette L. Lu et al. CELL
- Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung
- (2016) J S Woodworth et al. Mucosal Immunology
- Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K
- (2016) Seung Bin Cha et al. VACCINE
- Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool
- (2015) Christopher L. Karp et al. IMMUNOLOGICAL REVIEWS
- Qualification of a whole blood intracellular cytokine staining assay to measure mycobacteria-specific CD4 and CD8 T cell immunity by flow cytometry
- (2015) Benjamin M. Kagina et al. JOURNAL OF IMMUNOLOGICAL METHODS
- The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial
- (2015) Hennie Geldenhuys et al. VACCINE
- Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
- (2015) Adam Penn-Nicholson et al. VACCINE
- Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant
- (2015) Miriam Tendler et al. Frontiers in Immunology
- Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy
- (2014) Eleonora G. Thacher et al. AIDS
- OMIP-022: Comprehensive assessment of antigen-specific human T-cell functionality and memory
- (2014) Andrew J. Graves et al. CYTOMETRY PART A
- Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis
- (2014) S. Bertholet et al. JOURNAL OF IMMUNOLOGY
- Tuberculosis Vaccines and Prevention of Infection
- (2014) Thomas R. Hawn et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults
- (2013) Jaime Montoya et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis
- (2013) Mark T. Orr et al. JOURNAL OF CONTROLLED RELEASE
- Antibody-Dependent Cellular Cytotoxicity Is Associated with Control of Pandemic H1N1 Influenza Virus Infection of Macaques
- (2013) S. Jegaskanda et al. JOURNAL OF VIROLOGY
- High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples
- (2012) Eric P. Brown et al. JOURNAL OF IMMUNOLOGICAL METHODS
- The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine
- (2012) S. L. Baldwin et al. JOURNAL OF IMMUNOLOGY
- Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic Treatment
- (2012) Rhea N. Coler et al. JOURNAL OF INFECTIOUS DISEASES
- Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial
- (2012) Isabel Leroux-Roels et al. VACCINE
- Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
- (2011) Rhea N. Coler et al. PLoS One
- A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis
- (2011) Jaya Chakravarty et al. VACCINE
- A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
- (2010) Margaret E. Ackerman et al. JOURNAL OF IMMUNOLOGICAL METHODS
- A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis
- (2010) S. Bertholet et al. Science Translational Medicine
- The protective role of antibody responses duringMycobacterium tuberculosisinfection
- (2009) F. Abebe et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- TB vaccines: current status and future perspectives
- (2009) Claus Aagaard et al. IMMUNOLOGY AND CELL BIOLOGY
- Quality and Vaccine Efficacy of CD4+ T Cell Responses Directed to Dominant and Subdominant Epitopes in ESAT-6 from Mycobacterium tuberculosis
- (2009) C. S. Aagaard et al. JOURNAL OF IMMUNOLOGY
- Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells
- (2009) T. Lindenstrom et al. JOURNAL OF IMMUNOLOGY
- Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis
- (2009) Iván D. Vélez et al. VACCINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started